BioGaia AB (publ) Asset Resilience Ratio
BioGaia AB (publ) asset resilience ratio. BioGaia AB (publ) (BIOG-B) has an Asset Resilience Ratio of 50.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BIOG-B defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BioGaia AB (publ) (2006–2025)
Asset resilience ratio of BioGaia AB (publ) from 2006 to 2025. This chart shows how BioGaia AB (publ)'s Asset Resilience Ratio has changed over time. Read how much debt does BioGaia AB (publ) carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BioGaia AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of BioGaia AB (publ).
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr801.31 Million | 50.15% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr801.31 Million | 50.15% |
Asset Resilience Insights
- Very High Liquidity: BioGaia AB (publ) maintains exceptional liquid asset reserves at 50.15% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
BioGaia AB (publ) Industry Peers by Asset Resilience Ratio
Compare BioGaia AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
BioGaia AB (publ) Asset Resilience Ratio by Year (2006–2025)
BioGaia AB (publ) asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for BioGaia AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 50.15% | Skr801.31 Million ≈ $86.23 Million |
Skr1.60 Billion ≈ $171.95 Million |
-10.03pp |
| 2024-12-31 | 60.18% | Skr1.22 Billion ≈ $131.72 Million |
Skr2.03 Billion ≈ $218.89 Million |
-5.96pp |
| 2023-12-31 | 66.14% | Skr1.54 Billion ≈ $166.18 Million |
Skr2.33 Billion ≈ $251.27 Million |
-1.09pp |
| 2022-12-31 | 67.23% | Skr1.49 Billion ≈ $160.17 Million |
Skr2.21 Billion ≈ $238.26 Million |
-2.54pp |
| 2021-12-31 | 69.77% | Skr1.48 Billion ≈ $159.78 Million |
Skr2.13 Billion ≈ $229.01 Million |
-6.95pp |
| 2020-12-31 | 76.72% | Skr1.47 Billion ≈ $157.97 Million |
Skr1.91 Billion ≈ $205.90 Million |
+43.86pp |
| 2019-12-31 | 32.86% | Skr218.81 Million ≈ $23.55 Million |
Skr665.90 Million ≈ $71.66 Million |
-11.05pp |
| 2018-12-31 | 43.91% | Skr289.79 Million ≈ $31.19 Million |
Skr659.97 Million ≈ $71.02 Million |
-10.05pp |
| 2017-12-31 | 53.96% | Skr310.86 Million ≈ $33.45 Million |
Skr576.11 Million ≈ $62.00 Million |
+4.25pp |
| 2016-12-31 | 49.71% | Skr243.08 Million ≈ $26.16 Million |
Skr488.98 Million ≈ $52.62 Million |
+49.71pp |
| 2015-12-31 | 0.00% | Skr13.00K ≈ $1.40K |
Skr473.18 Million ≈ $50.92 Million |
0.00pp |
| 2014-12-31 | 0.00% | Skr13.00K ≈ $1.40K |
Skr415.61 Million ≈ $44.73 Million |
-0.02pp |
| 2013-12-31 | 0.02% | Skr80.00K ≈ $8.61K |
Skr383.42 Million ≈ $41.26 Million |
+0.01pp |
| 2012-12-31 | 0.02% | Skr80.00K ≈ $8.61K |
Skr517.02 Million ≈ $55.64 Million |
-0.01pp |
| 2011-12-31 | 0.03% | Skr80.00K ≈ $8.61K |
Skr279.83 Million ≈ $30.11 Million |
-0.01pp |
| 2010-12-31 | 0.04% | Skr80.00K ≈ $8.61K |
Skr227.82 Million ≈ $24.52 Million |
-0.01pp |
| 2009-12-31 | 0.04% | Skr80.00K ≈ $8.61K |
Skr179.81 Million ≈ $19.35 Million |
-0.52pp |
| 2007-12-31 | 0.56% | Skr620.00K ≈ $66.72K |
Skr110.77 Million ≈ $11.92 Million |
-0.35pp |
| 2006-12-31 | 0.91% | Skr830.00K ≈ $89.32K |
Skr90.76 Million ≈ $9.77 Million |
-- |
About BioGaia AB (publ)
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well … Read more